At 28.5% CAGR, The Global Brain Cancer Diagnostics Market Estimated to Record the Highest Revenue of US$ 7,378.57 million in 2028 - The Insight Partners

According to our latest study on "Brain Cancer Diagnostic Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Diagnostic Type, Cancer Type, End User, Tumor Size, and Geography," the market is expected to reach US$ 7,378.57 million in 2028 from US$ 1,639.10 million in 2022; it is estimated to grow at a CAGR of 28.5.% during 2022-2028. The report highlights the key factors driving the brain cancer diagnostic market growth and prominent players with their developments in the brain cancer diagnostic market. Key factors driving the market's growth are the rising incidence of brain cancer and the increasing number of cigarette smokers worldwide. However, the high cost of brain tumor diagnosis is expected to restrict the market growth during the forecast period.

Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.

Get Sample PDF Copy of Brain Cancer Diagnostics Market at:
https://www.theinsightpartners.com/sample/TIPRE00024461/?utm_source=OpenPR&utm_medium=10411

The list of companies operating in this report are:
THERMO FISHER SCIENTIFIC INC; Siemens Healthineers AG; GE Healthcare; MDxHealth; NantOmics; Biocept, Inc.; Koninklijke Philips N.V.; Canon Medical Systems; Hitachi, Ltd.; Neusoft Medical Systems; KITZ HEIDELBERG; GENPATH; NVIDIA CORPORATION; ONCORA MEDICAL; BIOMIND; SOPHIA AND ONCODNA; Clinspec Diagnostics; Raindance Technologies, Inc; ROCHE DIAGNOSTICS; and Illumina

Furthermore, the market is segmented based on type, application, and region in order to study it exhaustively and provide the data in a systematic manner. Speaking of competitive landscape, the study includes a list of leading companies along with their product and service offerings, strategic decisions, SWOT analysis, latest developments, market share captured, growth rate, and valuation. The challenges faced by these companies are analyzed and solutions for them are given as well.

Based on diagnostic type, the brain cancer diagnostics market is segmented into imaging test, lumbar puncture, biopsy, molecular testing, platform and services, cerebral arteriogram, neurological and hearing tests/neurocognitive assessments, electroencephalography (EEG), and others. Furthermore, the imaging test segment is sub-segmented into MRI, CT Scan, PET, and others. Similarly, the platform and services segment is sub-segmented into sample slide, autosampler unit, solutions and platform, and services. In 2022, the imaging test segment is likely to account for the largest share of the market.

Have Question? Speak to Analyst at: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00024461/?utm_source=OpenPR&utm_medium=10411

Rising Incidences of Brain Tumors Contributes Significantly to Market Growth
According to the American Society of Clinical Oncology (ASCO), in 2021, around 24,530 adults (13,840 men and 10,690 women) were diagnosed with primary cancerous tumors of the brain and spinal cord in the US. In a person's lifetime, the chances of having this form of tumor are fewer than 1%. Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases. Brain tumors can be fatal, severely impact the quality of life, and ultimately transform a patient's and their family's lives.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Brain Cancer Diagnostics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

Several market forces such as drivers and restraints and political, social, economic and technological advancements help shape up the industry in specific manner. All such forces are studied in detail to arrive at a market forecast which can help build the investment strategies in Brain Cancer.

Order a Copy of Brain Cancer Diagnostics Market Share, Strategies and Forecasts 2021-2028 Research Report at:
https://www.theinsightpartners.com/buy/TIPRE00024461/?utm_source=OpenPR&utm_medium=10411

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.